Prostate Cancer: Symptoms, Tests, and Treatment

September is Prostate Health Awaremeness month. Prostate cancer is the second most common cause of cancer-related deaths among American men. Learn more.
Source: FDA Consumer Health Information Updates - Category: Consumer Health News Source Type: news

Related Links:

Conclusiones: El tratamiento de la OMAM depende del estadio de la enfermedad; la mandibulectomía es un tratamiento efectivo en el estadio 3 y la secuestrectomía en el estadio 2; el estadio 1 suele controlarse con tratamiento conservador.ABSTRACT Introduction: Bisphosphonates are a family of drugs used to inhibit bone resorption. One of their secondary effects is osteonecrosis of the jaws (ONJ). In 2010, scientists began to publish cases of osteonecrosis of the jaws associated with a new drug, denosumab. In 2014 it was recommended to change the name of ONJ to medication-related osteonecrosis of the jaws (MONJ)...
Source: Revista Espanola de Cirugia Oral y Maxilofacial - Category: ENT & OMF Source Type: research
[Daily News] BUKOBA Regional Referral Hospital has acquired essential devices to screen cervical and prostate cancer in efforts to improve health delivery to majority of the population.
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news
Biochemical recurrence predicts survival in men with prostate cancer who have additional specific clinical risk factors, according to a systematic review.Reuters Health Information
Source: Medscape Pathology Headlines - Category: Pathology Tags: Hematology-Oncology News Source Type: news
Publication date: Available online 9 November 2018Source: Biochimica et Biophysica Acta (BBA) - Reviews on CancerAuthor(s): Christina C. Pierre, Shawn M. Hercules, Clayton Yates, Juliet M. DanielAbstractThe POZ-ZF transcription factor Kaiso was discovered two decades ago as a binding partner for p120ctn. Since its discovery, roles for Kaiso in diverse biological processes (epithelial-to-mesenchymal transition, apoptosis, inflammation) and several signalling pathways (Wnt/β-catenin, TGFβ, EGFR, Notch) have emerged. While Kaiso's biological role in normal tissues has yet to be fully elucidated, Kaiso has been incre...
Source: Biochimica et Biophysica Acta (BBA) Reviews on Cancer - Category: Cancer & Oncology Source Type: research
This study was designed to produce the optimal Alg-g-P(NIPAAm) hydrogel with respect to localised delivery of DNA nanoparticles as a potential medical device for those with castrate resistant prostate cancer (CRPC). Given that CRPC typically disseminates to bone causing pain, morbidity and a plethora of skeletal related events, a copolymer based hydrogel was designed to for long term release of therapeutic DNA nanoparticles.The nanoparticles were comprised of plasmid DNA (pDNA), complexed with an amphipathic cell penetrating peptide termed RALA that is designed to enter cells with high efficiency. Alginate MW and M/G ratio...
Source: Materials Science and Engineering: C - Category: Materials Science Source Type: research
Publication date: Available online 9 November 2018Source: Urology Case ReportsAuthor(s): Takashi Ando, Kazuhiro Watanabe, Takaki Mizusawa, Akiyoshi Katagiri
Source: Urology Case Reports - Category: Urology & Nephrology Source Type: research
ConclusionsResults support the efficacy, safety, and QoL associated with padeliporfin focal treatment for low/intermediate risk localized PCa.ResumenObjetivosExplorar la proporción de pacientes con cáncer de próstata localizado (CaP) de mayor riesgo que se convertiría en una biopsia negativa con seguridad 12 meses después de la terapia focal no térmica con terapia fotodinámica dirigida vascular de padeliporfina (TFV).MétodosEstudio multicéntrico en un escenario de antígeno prostático específico (PSA) ≤ 20 ng/ml y patr&oacu...
Source: Actas Urologicas Espanolas - Category: Urology & Nephrology Source Type: research
Publication date: Available online 10 November 2018Source: European UrologyAuthor(s): Sebastian Berg, Alexander P. Cole, Marieke J. Krimphove, Junaid Nabi, Maya Marchese, Stuart R. Lipsitz, Joachim Noldus, Toni K. Choueiri, Adam S. Kibel, Quoc-Dien TrinhAbstractA previous study comparing external beam radiation therapy with/without brachytherapy (EBRT ± BT) and radical prostatectomy (RP) for high-risk localized prostate cancer (PCa) did not find a difference in overall survival (OS) between the treatments. However, this study was limited by short follow-up and assessment of OS in patients of divergent age ...
Source: European Urology - Category: Urology & Nephrology Source Type: research
ConclusionsIncorporation of MRI into surveillance protocols at Medicare reimbursement rates and decreasing the intensity of repeat testing may be cost-effective options for men opting for conservative management of low-risk prostate cancer.Patient summaryOur study modeled outcomes for men with low-risk prostate cancer undergoing watchful waiting, immediate treatment, or active surveillance with different follow-up schedules. We found that conservative management of low-risk disease optimizes health outcomes and costs. Furthermore, we showed that decreasing the intensity of active surveillance follow-up and incorporating ma...
Source: European Urology - Category: Urology & Nephrology Source Type: research
Publication date: Available online 9 November 2018Source: European UrologyAuthor(s): Daniël F. Osses, Sebastiaan Remmers, Fritz H. Schröder, Theo van der Kwast, Monique J. RoobolAbstractWe assessed the effect of screening in the European Randomized study of Screening for Prostate Cancer (ERSPC) Rotterdam pilot 1 study cohort with men randomized in 1991–1992. A total of 1134 men were randomized on a 1:1 basis to a screening (S) and control (C) arm after prostate-specific antigen (PSA) testing (PSA ≥10.0 ng/ml was excluded from randomization). Further PSA testing was offered to all men in the S-arm wi...
Source: European Urology - Category: Urology & Nephrology Source Type: research
More News: Cancer | Cancer & Oncology | Learning | Prostate Cancer | Universities & Medical Training